According to the medical account carried by ARN, the child experienced around 110 seizures daily despite seven treatment approaches. Following genetic diagnosis, the team obtained ABS-1230 through compassionate access, working with federal and Dubai health authorities.
Doctors report that seizures stopped within thirty minutes of the first dose and that the child left hospital a week later. The medicine remains experimental and is being studied in clinical trials. Follow-up of a single patient cannot establish its general effectiveness or the durability of the response.